SV Health Investors
VC Fund
Boston, United States
SV Health Investors is a VC fund in Boston focused on Biotechnology and Health Care. SV Health Investors, formerly SV Life Sciences, is a leading healthcare and life sciences venture capital and growth equity firm.Their goal is to transform healthcare – one investment at a time – by supporting the entrepreneurs who create and build breakthrough companies and treatments.With over $2 billion in capital under management inseven private healthcare funds, a 20-year track record in the US and Europe and offices in Boston, San Francisco and London, SV Health Investors drives game-changing innovation.
- Total investments:
- 248
- Last investment:
- Lead investor:
- 23%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries SV Health Investors invests in
Stages SV Health Investors invests in
Countries SV Health Investors invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Eugene Hill
|
|||
Bruce A. Peacock
|
|||
Bruce Cerullo
|
|||
Dan Burgess
|
|||
David Guyer
|
|||
| See all 18 contacts → | |||
Investment Focus
Industry
- Biotechnology 88 (35%)
- Health Care 83 (33%)
- Medical 44 (18%)
- Medical Device 36 (15%)
- Therapeutics 31 (13%)
Stage
- Series A 53 (21%)
- Series B 43 (17%)
- Funding Round 29 (12%)
- Series D 20 (8%)
- Seed 19 (8%)
Country
- United States 99 (40%)
- United Kingdom 21 (8%)
- Switzerland 3 (1%)
- Australia 2 (1%)
- India 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Eugene Hill
Chairman
|
Chairman | Total investments: 3 | Find email | |
|
Bruce A. Peacock
Venture Partner
|
Venture Partner | Total investments: 3 | Find email | |
|
Bruce Cerullo
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
|
Dan Burgess
Venture Partner
|
Venture Partner | Total investments: 3 | Find email | |
|
David Guyer
Venture Partner
|
Venture Partner | Total investments: 12 | Find email | |
| See all 18 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AdvanCell
|
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M / Series D / Jul 15, 2026 | |
Mestag Therapeutics
|
Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology. | $40M / Venture - Series Unknown / Mar 17, 2026 | |
TRex Bio
|
TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $50M / Jan 27, 2026 | |
HPS / PayMedix
|
PayMedix began as the healthcare payment platform for Health Payment Systems (HPS) in 2008. HPS, headquartered in Milwaukee, Wisconsin, is a privately held healthcare technology and services organization with an independent network of 96 hospital facilities and 22,600 individual providers. PayMedix has processed more than $5 billion in medicalpayments for hospital systems and physician practices and can be implemented with any PPO or HMO network. | $16M / Private Equity / Jan 13, 2026 | |
Artios Pharma
|
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $115M / Series D / Nov 17, 2025 | |
Imbria Pharmaceuticals
|
Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need. Weare propelled by a deep scientific interest in cellular metabolism and the mitochondria, and are guided by both values and a code of business conduct built upon our commitment to always put the patients, families and communities we serve at the forefront of all that we do. | Series B / Nov 17, 2025 | |
Dualitas Therapeutics
|
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders and other conditions. With a growing collection of innovative cell surface proximity engagers and our in-house DualScreen™ discovery engine, our pipeline | $65M / Series A / Sep 16, 2025 | |
Alchemab Therapeutics
|
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases. | $32M / Series A / Sep 09, 2025 | |
Draig Therapeutics
|
Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses. | $140M / Series A / Jun 18, 2025 | |
|
Draig Therapeutics
|
Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses. | $140M / Series A / Jun 18, 2025 | |
| See all 248 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does SV Health Investors invest in?
SV Health Investors invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 248 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact SV Health Investors?
Public channels for SV Health Investors include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SV Health Investors?
The team at SV Health Investors includes Eugene Hill (Chairman), Bruce A. Peacock (Venture Partner) and Bruce Cerullo (Operating Partner), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
